June 18, 2021. Host Ben Shaberman interviews Dr. Daniel Chung, chief medical officer at SparingVision, which is developing a gene-agnostic therapy to preserve cone vision in people with retinitis pigmentosa, Usher syndrome, and related conditions. A clinical trial launch for the emerging treatment, known as SPVN06, is planned for late 2021 or early 2022.
